Physician profile
Mark E Burnett
NPI 1104182393
$1,343.10
in general payments reported to CMS, 2019-2025
13 companies · $558 in 2025
The $558 reported for 2025 was more than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $58.59 · 2022: $81.93 · 2023: $213 · 2024: $431 · 2025: $558.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Education: $99.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,102.83 |
| Education | $99.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $193.48 | 2022-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $169.12 | 2024-2025 | |
| Lilly USA, LLC | $152.19 | 2021-2025 | Taltz, Ebglyss, Zepbound |
| Novartis Pharmaceuticals Corporation | $130.77 | 2023-2025 | |
| Organon LLC | $122.13 | 2025 | Nexplanon |
| Galderma Laboratories, L.P. | $117.22 | 2022-2025 | Nemluvio, Aklief |
| Incyte Corporation | $108.69 | 2024-2025 | Opzelura |
| Abbvie INC. | $93.98 | 2024-2025 | |
| Genzyme Corporation | $79.56 | 2023-2025 | |
| Janssen Biotech, INC. | $79.51 | 2022-2025 | Tremfya |
| Organogenesis INC. | $41.45 | 2021 | |
| Journey Medical Corporation | $33.34 | 2025 | |
| Merz North America, INC. | $21.66 | 2023 | Xeomin |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Burnett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.